Olema Pharmaceuticals, Inc.

OLMA

N/A

NASDAQBiotechnology🇺🇸North America122 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 30, 2026

27w

Drug Pipeline

Drug Name	Phase	Indication	Designations
Letrozole-matching placebo	Phase 3	Breast Cancer	-
Palazestrant	Phase 3	Breast Cancer	-
OP-1250	Phase 2	Hormone Receptor Positive Breast Carcinoma	-

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

Jun 30, 2026Palazestrant

Primary completion for Palazestrant trial (NCT06016738) in Breast Cancer

Regulatory Approvals

OLMA News